Get started
Atossa Therapeutics, Inc.Atossa Therapeutics, Inc.Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

ATOS trade ideas

Here We Go (Again?) With ATOSThis is familiar territory with ATOS . Not only is there a very clear and significant support level on the chart, there's also a multi-year level of resistance the ATOS is sitting at right now. The biggest question is Now What? " Earlier this month, Atossa revealed data from a Phase 2 Endoxifen study in breast cancer. It met primary and secondary endpoints. The Phase 2 study was conducted on behalf of Atossa by Avance Clinical, a leading Australian CRO. Based on the results, the company also discussed its plan to apply to the FDA for approval to begin a clinical study in the US 'as soon as possible.' With meaningful results and potential for more clinical trials in the US, ATOS could be on the list of biotech penny stocks on Robinhood to watch this summer ." Quote Source: 7 Penny Stocks On Robinhood To Watch In June 2021
NASDAQ:ATOS
by PennyStocks101
13
ATOS BIG BUY/LONG POTENTIAL 2.65 to 140.00 By Mid 2022!ICKER CODE: ATOS Company Name: ATOSSA THERAPEUTICS, INC Industry: US Stocks Health Technology Medical Specialties Position Proposed: BUY FOMO BUY ENTRY: NOW READY (4.00-5.20) NEXT BUY ENTRY: (2,65 - 3.35) 1st Partial Take Profit: 140.00 (Mid 2022) 2nd Partial Take Profit: 200.00 (Mid 2024) 3RD Partial Take Profit: 320.00 (2027) 1st PARTIAL SHORT TERM TP: 30:200 2nd PARTIAL SHORT TERM TP: 140.00 Stop Loss: 3.00 Technical Analysis 1. FALLING WEDGE PATTERN (COMPLETED ) 2. HEAD & SHOULDERS PATTERN (PARTIALLY COMPLETE) 2. Area of Confluence on EMA & structure level 4. Fibonacci Retracement at 0.618 OR 0.786 5. Safest Take Profit will land 80 % equivalent to the length of head and neckline level 2 of Fibonacci Expansion Blue Zone
NASDAQ:ATOSLong
by traderprosignals
6
This looks...Familiar on ATOSThis is a very interesting level for ATOS right now. The last two times before this most recent instance the stock failed to break through and hold this level. It was able to do that briefly this year but unsustainable. After consolidating this last time around, what's the catalyst to actually spark a firm move? I think a lot will come down to the next steps for AT-301 to be honest: "Recently ATOS has received phase 2 initiation approval from the Swedish Medical Product Agency for its oral Endoxifen. This drug targets mammographic breast density (MBD), to reduce and eradicate potential tumors. MBD affects millions worldwide and can reduce the effectiveness of mammograms...Doctors around the world depend on mammogram studies to detect cancer through breast density. With a drug such as Endoxifen, it would increase the ability for earlier diagnosis, which in turn could reduce breast cancer incidence... This is a large breakthrough for the company and considering the incidence of breast cancer around the world, Endoxifen could be a big deal moving forward. Investors should stay up to date with any news regarding this compound, as it is Atossa’s flagship product. However, it does have a sizable pipeline that includes a Covid-19 nasal spray treatment known as AT-301." Quote Source: 4 Top Biotech Penny Stocks To Watch In The Second Half Of June 2021
NASDAQ:ATOS
by PennyStocks101
ATOS - Dump or Buy? 🤷-Atossa Therapeutics Inc (ATOS) stock is trading at $4.76 as of 10:00 AM on Friday, Jun 4, a rise of $0.32, or 7.09% from the previous closing price of $4.44. The stock has traded between $4.55 and $4.92 so far today. Volume today is light. So far 2,739,675 shares have traded compared to average volume of 13,614,422 shares. -Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in the US. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. -Prognosticator Edward Woo lifted said price target on Atossa to an even $8 per share from the previous $7.75. The new level is slightly more than twice the most recent closing price of the clinical-stage biotech. Almost needless to say, Woo has a buy rating on the stock; this remained unchanged with the price target raise. -Atossa's most promising pipeline drug is Endoxifen, an oral treatment for breast cancer. Recently, it has also been developing a pair of medications for COVID-19. Since breast cancer is a particularly devastating and relatively widespread ailment, the company has great upside potential if Endoxifen tests well. -Woo has been very bullish on Atossa from the get-go. He initiated coverage on the stock with a buy recommendation last September. Slapping a $7 per-share price target on it at the time, he wrote that "this valuation appropriately balances out the company's high risks with the company's high growth prospects and large upside opportunities."
NASDAQ:ATOSLong
by caldooninvestment
28
$ATOS Target 4.09 for 29.43% $ATOS Target 4.09 for 29.43% Or next add level is at 2.23 Support at the MA of RSI... let's go towards target 🙌🏼 — On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average. I start every position with 1% of my account and build from there as needed and as possible. I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed. GL and happy trading.
NASDAQ:ATOSLong
by SPYder_QQQueen_Trading
2
$ATOS entry PTs 2.30 Target PTs 4.75-5.50-7 and higherPivoting off Support and up-trending towards Resistance, time sequence within Wave analysis Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. Atossa Therapeutics, Inc. has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the potential treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
NASDAQ:ATOSLong
by BADQOMOCAWGOWLD